Research Initiative: Thalidomide Study (2023–2024)
The Trust sponsored a study to assess the Efficacy of Low-Dose versus standard - Dose Thalidomide in Patients with Transfusion-Dependent Thalassemia during 2023- 2024. Twelve eminent haematologists conducted the Study at four centres with 188 participants over 18 months.
The Study concluded that:
- The low-dose thalidomide was as efficacious as the standard dose in reducing transfusion requirements.
- Thalidomide is well tolerated and can be considered as an adjunct to an optimal transfusion-chelation regimen under close monitoring in a resource-constrained setting.
The findings of the Study are with the Government for its due consideration.